

Proposed Project Scope

Bevacizumab with chemotherapy in locally advanced or metastatic endometrial cancer

Date: July 2025

Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of bevacizumab with chemotherapy in locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy.

Table I: Policy Questions

Item	Policy Question
1	Should bevacizumab be publicly reimbursed with chemotherapy in locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy?

Table II: Products Available in Canada

Product	Manufacturer
Bevacizumab	n/a

Project Description

Table III: Project Scope

Criteria	Description
Population	Adult patients with locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy [prior line of therapy includes first line therapy (immunotherapy and platinum-based chemotherapy) and second line therapy (pembrolizumab monotherapy, pembrolizumab and lenvatinib, or chemotherapy as multi or single agent)]
Intervention(s)	Bevacizumab and chemotherapy (carboplatin and paclitaxel)
Comparators	Chemotherapy (carboplatin and paclitaxel) Pembrolizumab monotherapy (for patients with dMMR/MSI-H disease) Pembrolizumab and lenvatinib
Outcomes	Progression free survival, overall response rate, overall survival, adverse events.

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of bevacizumab with chemotherapy in locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy?
2	What are the harms associated with bevacizumab with chemotherapy in locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy?
3	What is the expected cost of bevacizumab with chemotherapy in locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.